Cargando…

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines

We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Luczkowiak, Joanna, Rivas, Gonzalo, Labiod, Nuria, Lasala, Fátima, Rolo, Marta, Lora‐Tamayo, Jaime, Mancheno‐Losa, Mikel, Rial‐Crestelo, David, Pérez‐Rivilla, Alfredo, Folgueira, María Dolores, Delgado, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828064/
https://www.ncbi.nlm.nih.gov/pubmed/36319593
http://dx.doi.org/10.1002/jmv.28268
_version_ 1784867186402131968
author Luczkowiak, Joanna
Rivas, Gonzalo
Labiod, Nuria
Lasala, Fátima
Rolo, Marta
Lora‐Tamayo, Jaime
Mancheno‐Losa, Mikel
Rial‐Crestelo, David
Pérez‐Rivilla, Alfredo
Folgueira, María Dolores
Delgado, Rafael
author_facet Luczkowiak, Joanna
Rivas, Gonzalo
Labiod, Nuria
Lasala, Fátima
Rolo, Marta
Lora‐Tamayo, Jaime
Mancheno‐Losa, Mikel
Rial‐Crestelo, David
Pérez‐Rivilla, Alfredo
Folgueira, María Dolores
Delgado, Rafael
author_sort Luczkowiak, Joanna
collection PubMed
description We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross‐neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID‐19 convalescents except for BA.4/5. Avidity of RBD‐binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS‐CoV‐2 sequences are required to induce high avidity cross‐neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments.
format Online
Article
Text
id pubmed-9828064
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98280642023-01-10 Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines Luczkowiak, Joanna Rivas, Gonzalo Labiod, Nuria Lasala, Fátima Rolo, Marta Lora‐Tamayo, Jaime Mancheno‐Losa, Mikel Rial‐Crestelo, David Pérez‐Rivilla, Alfredo Folgueira, María Dolores Delgado, Rafael J Med Virol Short Communications We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross‐neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID‐19 convalescents except for BA.4/5. Avidity of RBD‐binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS‐CoV‐2 sequences are required to induce high avidity cross‐neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments. John Wiley and Sons Inc. 2022-11-10 2023-01 /pmc/articles/PMC9828064/ /pubmed/36319593 http://dx.doi.org/10.1002/jmv.28268 Text en © 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Luczkowiak, Joanna
Rivas, Gonzalo
Labiod, Nuria
Lasala, Fátima
Rolo, Marta
Lora‐Tamayo, Jaime
Mancheno‐Losa, Mikel
Rial‐Crestelo, David
Pérez‐Rivilla, Alfredo
Folgueira, María Dolores
Delgado, Rafael
Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title_full Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title_fullStr Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title_full_unstemmed Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title_short Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
title_sort cross neutralization of sars‐cov‐2 omicron subvariants after repeated doses of covid‐19 mrna vaccines
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828064/
https://www.ncbi.nlm.nih.gov/pubmed/36319593
http://dx.doi.org/10.1002/jmv.28268
work_keys_str_mv AT luczkowiakjoanna crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT rivasgonzalo crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT labiodnuria crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT lasalafatima crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT rolomarta crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT loratamayojaime crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT manchenolosamikel crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT rialcrestelodavid crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT perezrivillaalfredo crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT folgueiramariadolores crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines
AT delgadorafael crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines